Life Sciences Tools and Services

Medpace

Medpace released FY2026 Q1 earnings on April 22 After-Market EST, but actual revenue and EPS data are unavailable.

Medpace Announces Strong Q1 2026 Earnings, CEO Jesse Geiger to Resign

Medpace to Release FY2026 Q1 Earnings on April 22 After-Market EST, Forecast Revenue USD 697.63 M, EPS USD 3.8825

Medpace CEO Exercised Stock Options and Sold Shares

Medpace Investigated for Significant Decline in Billing-to-Revenue Ratio

Medpace released FY2025 Q4 earnings on February 9 After-Market EST, actual revenue USD 708.45 M (forecast USD 690.93 M), actual EPS USD 4.6629 (forecast USD 4.1933)

Medpace released FY2025 Annual Earnings on February 9 After-Market (EST), Actual Revenue USD 2.53 B (Forecast USD 2.511 B), Actual EPS USD 15.28 (Forecast USD 14.8018)

Medpace to Release FY2025 Q4 Earnings on February 9 After-Market EST, Forecast Revenue USD 690.93 M, EPS USD 4.1933

PineStone Asset Management Reduced Its Stake in Medpace

Swedbank AB Reduces Stake in Medpace Holdings

XTX Topco Ltd Large Reduction in Medpace Holdings Shares

Medpace Holdings CEO Announces Sale of Common Stock

Medpace CEO Sells Company Shares

Medpace Holdings EVP Susan E. Burwig Reports Sale of Common Stock

Medpace Holdings Hits New 52-Week High and Reports Strong Quarterly Earnings

Medpace CEO August J. Troendle Disposes of Common Stock

Medpace VP Files Form 144 to Prepare for Sale of 20,000 Restricted Shares

Empirical Finance LLC Increased Holdings in Medpace Holdings in Q2

Medpace insiders sold $18,376,705 worth of shares

Medpace CEO Disposes of Company's Common Stock

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MEDP

SBIO

ARKG

IDNA

Medpace Holdings shareholders approved charter amendments to remove supermajority voting requirements and limits on calling special meetings during the annual meeting on May 15, 2026. The changes will take effect on May 18, 2026. Additionally, shareholders owning at least 25% of voting power can now call special meetings, subject to certain conditions. A non-binding proposal for calling special meetings did not pass.

PUBT

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

iShares US Healthcare Providers

SPDR S&P Health Equip

Health Care Select Sector SPDR

iShares US Medical Devices

Direxion S&P Biotech Bear 3X

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

Northwestern Mutual Wealth Management Co. significantly increased its stake in Medpace Holdings, Inc. by 24,930.4% during Q4, acquiring 100,968 shares, bringing its total to 101,373 shares valued at approximately $56.9 million. Institutional investors now own 77.98% of Medpace. Analysts have mixed ratings on the stock, with a consensus target price of $467.08. Medpace reported strong Q1 earnings, beating estimates with $4.28 EPS and $706.6 million in revenue, up 26.5% year-over-year.

Market Beat

Jefferies Financial

Mizuho Financial

Mizuho Financial Group, Inc.

ROYAL BANK OF CANADA

Northwestern Mutual Wealth Management Co. Purchases 100,968 Shares of Medpace Holdings, Inc. $MEDP

Robbins Geller Rudman & Dowd LLP announces that investors of Medpace Holdings Inc. who suffered losses between April 22, 2025, and February 9, 2026, can seek to be lead plaintiffs in a class action lawsuit. The lawsuit alleges violations of the Securities Exchange Act, including misleading statements about the company's book-to-bill ratio. Interested investors must apply by June 8, 2026.

PR Newswire

INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The Law Offices of Frank R. Cruz announced that investors who lost money in Medpace Holdings, Inc. (NASDAQ: MEDP) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that between April 22, 2025, and February 9, 2026, the company misrepresented its projected book-to-bill ratio and downplayed the impact of cancellations on its business. Investors are encouraged to participate before the lead plaintiff deadline of June 8, 2026, for more information or to join the lawsuit.

16:24 ETMedpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The DJS Law Group has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for securities law violations, specifically for making false and misleading statements regarding its financial performance. The lawsuit covers shareholders who purchased shares between April 22, 2025, and February 9, 2026, with a deadline for participation set for June 5, 2026. Investors are encouraged to contact the firm for potential lead plaintiff appointments and to recover losses incurred during the class period.

03:28 ETMedpace Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MEDP

Rosen Law Firm is reminding investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, of the June 8, 2026, deadline to lead a securities fraud lawsuit. The firm claims that Medpace misled investors about its backlog cancellation rates, leading to damages when the truth emerged. Investors can join the class action without upfront costs. For more information, contact Phillip Kim, Esq. at 866-767-3653 or via email.

02:27 ETMEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit

Medpace(MEDP.US)